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More than 30 yr ago, the first cases of AIDS 
were reported, followed 2 yr later by the iden-
tification of the causative agent of this disease, 
HIV. There were 2.6 million new infections 
in 2009, of which 1.8 million occurred in sub-
Saharan Africa where the majority of new 
infections continue to occur (http://www 
.unaids.org). The need for a safe and efficacious 
HIV preventive vaccine is as urgent as 30 yr 
ago and remains the best long-term strategy to 
prevent the transmission of HIV/AIDS (Cohen, 
2008). In addition to the lack of a prophylactic 
vaccine, as yet, no strong correlate of protec-
tive immunity has been directly established. 
However, considering classical vaccinology 
and the principles underlying the partial immune 
control of HIV-1 infection, it has been postu-
lated that an effective vaccine will need to pro-
duce coordinated B and T cell responses (Burton 
et al., 2004; Pantophlet and Burton, 2006; 
McElrath and Haynes, 2010). Notably, passive 
immunization with monoclonal antibodies 
(Abs [mAbs]) derived from HIV-1–infected 
individuals has demonstrated the potential for 
neutralizing Abs (nAbs) as a protective com-
ponent of a vaccine-induced immunological 
memory response (Mascola et al., 1999; Shibata 
et al., 1999; Baba et al., 2000; Parren et al., 
2001; Watkins et al., 2011). Consequently, 
demonstrating, as we do here, that immuniza-
tion can induce Abs that can broadly neutralize 
HIV-1 is a major goal of HIV-1 vaccine de-
velopment (Stamatatos et al., 2009; Mascola 
and Montefiori, 2010).
Potent nAbs, which neutralize up to 90% 
of virus strains tested, have been recently iso-
lated (Walker et al., 2009, 2011; Burton and 
CORRESPONDENCE  
Robin A. Weiss: 
r.weiss@ucl.ac.uk
Abbreviations used: Ab, anti-
body; Fab, antigen-binding 
fragment; IC50, 50% inhibitory 
concentration; nAb, neutralizing 
Ab; NHP, nonhuman primate; 
RLU, relative light unit; sCD4, 
soluble CD4; SHIV, chimeric 
simian-HIV.
Potent and broad neutralization of HIV-1  
by a llama antibody elicited by immunization
Laura E. McCoy,1,2 Anna Forsman Quigley,1,2 Nika M. Strokappe,4  
Bianca Bulmer-Thomas,1,2 Michael S. Seaman,5 Daniella Mortier,6  
Lucy Rutten,4 Nikita Chander,1,2 Carolyn J. Edwards,1,2 Robin Ketteler,3 
David Davis,6 Theo Verrips,4 and Robin A. Weiss1,2
1Wohl Virion Centre and 2Medical Research Council (MRC) Centre for Medical Molecular Virology, Division of Infection  
and Immunity; and 3MRC Laboratory for Molecular Cell Biology; University College London, London WC1E 6BT, England, UK
4Biomolecular Imaging, Department of Biology, Institute of Biomembranes, Faculty of Science, Utrecht University,  
3584 CH Utrecht, Netherlands
5Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
6Department of Virology, Biomedical Primate Research Centre, 2280 GH Rijswijk, Netherlands
Llamas (Lama glama) naturally produce heavy chain–only antibodies (Abs) in addition to 
conventional Abs. The variable regions (VHH) in these heavy chain–only Abs demonstrate 
comparable affinity and specificity for antigens to conventional immunoglobulins despite 
their much smaller size. To date, immunizations in humans and animal models have yielded 
only Abs with limited ability to neutralize HIV-1. In this study, a VHH phagemid library 
generated from a llama that was multiply immunized with recombinant trimeric HIV-1 
envelope proteins (Envs) was screened directly for HIV-1 neutralization. One VHH, L8CJ3 
(J3), neutralized 96 of 100 tested HIV-1 strains, encompassing subtypes A, B, C, D, BC, AE, 
AG, AC, ACD, CD, and G. J3 also potently neutralized chimeric simian-HIV strains with HIV 
subtypes B and C Env. The sequence of J3 is highly divergent from previous anti–HIV-1 
VHH and its own germline sequence. J3 achieves broad and potent neutralization of HIV-1 
via interaction with the CD4-binding site of HIV-1 Env. This study may represent a new 
benchmark for immunogens to be included in B cell–based vaccines and supports the 
development of VHH as anti–HIV-1 microbicides.
© 2012 McCoy et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
1092 HIV-1 broadly neutralizing llama antibody | McCoy et al.
improvement on anti–HIV-1 mAbs or Ab fragments previ-
ously isolated after immunization, including but not limited 
to other anti–HIV-1 VHH, and demonstrates for the first 
time that a mammalian immune response to HIV-1 Env 
can elicit an Ab that as a VHH fragment is as broadly cross-
reactive against a large panel of HIV-1 variants as the best 
full-length conventional human mAbs produced as a result 
of natural infection.
RESULTS
Llama immunization and phagemid library generation
A Lama glama (designated llama 8) was injected intramuscularly 
with a mixture of Gp140 trimers derived from a subtype BC 
HIV-1 strain, CN54 (Gp140CN54), and a subtype A strain, 
92UG037 (Gp140UG37). Llama 8 was immunized in parallel 
with another llama, and the library generated from the other 
llama is described elsewhere (Strokappe et al., 2012). Previ-
ously, llamas immunized with monomeric HIV-1 proteins had 
been shown to produce anti–HIV-1 VHH with limited breadth 
and neutralization potency (Forsman et al., 2008; Hinz et al., 
2010; Koh et al., 2010). In addition, the neutralization activity 
induced by human immunization trials (VAX04) with mono-
meric Env has been reported to be inferior to that induced by 
trimer immunization of NHPs (Sundling et al., 2010). Thus, 
this subsequent immunization schedule included trimeric Env 
with the aim that the functional glycoprotein spike of infec-
tious HIV-1 would be more accurately mimicked and presented 
to the llama immune system. The protein immunogens were 
administered with Stimune adjuvant seven times as described 
in the immunization schedule depicted in Table S1. The llama 
immune response was satisfactory, as indicated by an increase 
in the ability of postimmunization sera, relative to preimmuni-
zation sera, to bind to the immunogen Env proteins Gp140UG37 
and Gp140CN54 in ELISA (Fig. 1, A and B). Retrospectively, 
sera from llama 8 were assessed for neutralization abilities 
against pseudovirus with 92UG037 or the CN54 primary iso-
late. Neutralization against both viruses was seen with sera 
taken 122 d after immunization compared with sera taken on 
day 0 (Fig. 1, C and D). For the neutralization-sensitive viruses 
IIIB and 93MW956, appreciably higher ID50 values were seen 
with the day 122 sera compared with the ID50 values of the 
homologous viruses (Fig. 1 E). In contrast, the ID50 value 
obtained for Bal26 (tier 1b neutralization sensitivity) was only 
slightly higher than those calculated for the homologous 
viruses, and the ID50 for 96ZM956 (tier 2) was similar to the 
ID50 values for the homologous viruses (Fig. 1 E). Immune 
phagemid libraries were constructed using blood collected 
from llama 8 on day 122, and library construction followed. In 
brief, RNA was extracted from purified peripheral blood lym-
phocytes (Chomczynski and Sacchi, 2006) from postimmuni-
zation blood at day 122 and cDNA generated to enable the 
amplification of the conventional and heavy chain IgG reper-
toire. The heavy chain–only Ab cDNAs were separated by gel 
electrophoresis and used as a template in a nested PCR, which 
enabled the isolation of the VHH repertoire via the insertion 
of restriction sites. The resulting cDNA fragments were ligated 
Weiss, 2010; Wu et al., 2010; Scheid et al., 2011) from pa-
tients, substantially raising the benchmark for nAbs elicited 
by immunization. Notably, many of these nAbs neutralize 
HIV-1 via interaction with the CD4-binding site of HIV-1 
envelope protein (Env), and a considerable number of such 
nAbs have now been isolated from multiple donors (Corti 
et al., 2010), validating the CD4-binding site as target for 
protective Abs. Furthermore, the neutralization activity in 
many broadly neutralizing human sera is reported to be me-
diated by CD4-binding site–targeting Abs (Li et al., 2007). 
However, immunization in a variety of animal models has 
rarely produced any mAbs with potency or breadth compa-
rable even with the long-established human nAbs such as b12 
(Burton et al., 1991). Moreover, the potency and breadth of 
immunization-elicited nAbs (Zhang et al., 2007; Forsell 
et al., 2009) have not by any means approached the standard 
of the newly described human mAbs obtained during HIV-1 
infection (Walker et al., 2009, 2011; Wu et al., 2010), 
although recently robust Env-specific memory B cell re-
sponses have been seen in immunized nonhuman primates 
(NHPs; Sundling et al., 2010). Neutralization with plasma 
samples was predominantly restricted to clade B tier 1 viruses 
with one representative from clades A and C neutralized and 
detectable and less potent neutralization against some tier 
2 viruses (Sundling et al., 2010). It should be noted that antigen-
binding fragments (Fabs) of CD4-induced epitope mAbs, 
such as 17b (Thali et al., 1993), exhibit the ability to neutralize 
viruses that the corresponding full-length IgG cannot 
(Moulard et al., 2002) and that it has been possible to induce 
17b-like mAb after immunization (Vaine et al., 2010). How-
ever, the breadth of the 17b Fab was evaluated as neutralizing 
HIV-1 with comparable efficiency to b12 IgG (Moulard 
et al., 2002), which in contrast was less effective in Fab form 
(Moulard et al., 2002; Labrijn et al., 2003), as are the majority 
of Fabs compared with their corresponding whole Ab mole-
cules (Ugolini et al., 1997).
The natural occurrence of llama heavy chain–only Abs 
(Hamers-Casterman et al., 1993) and the independent neu-
tralization properties of their variable domains, i.e., the single- 
domain VHH, enabled screening of the VHH without the 
need for random recombination of heavy and light chains. 
Preliminary immunization of llamas with monomeric Gp120 
previously led to the isolation of neutralizing VHH against 
HIV-1 (Forsman et al., 2008; Hinz et al., 2010; Koh et al., 
2010). Given the limitations of the previous anti-HIV VHH, 
a new neutralization screening process was developed to 
isolate the extremely broad and potent VHH J3 described 
herein. The power of the screening process was increased by 
removing the biopanning stage, which favors VHH that bind 
to recombinant HIV-1 Env but does not distinguish between 
virus neutralizing and nonneutralizing binding properties. 
Consequently, in this study, the direct neutralization screen-
ing of a phagemid VHH library, generated from a llama 
immunized with two recombinant HIV Gp140 proteins, yielded 
a llama VHH that neutralizes 96% of HIV-1 isolates tested via 
interaction with a CD4-binding site epitope. This is a marked 
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(Walker et al., 2009). Consequently, a new screening method 
was developed whereby the VHH were assessed directly for 
their ability to neutralize HIV-1 pseudovirus without any 
prior selection for the ability to bind to Env or compete with 
characterized anti–HIV-1 mAb or sCD4.
The direct neutralization screening method involved 
robotically isolating 2,816 VHH clones plated out onto agar 
from the phagemid library into 384-well master plates. The 
VHH clones were expressed in 96-well plates and targeted to 
the periplasm of the E. coli. Subsequently, the VHH-containing 
periplasmic extract was harvested by freeze-thawing fol-
lowed by filtration and assessed for the ability to neutralize 
the subtype A MS208.A1 and subtype C 93MW956.1 HIV-1 
pseudoviruses in parallel via the TZM-bl cell-based assay, 
whereby infection by HIV-1 elicits the expression of firefly 
luciferase and can be quantitatively measured by light emis-
sion. Neutralization was defined as reduction in relative light 
units (RLUs) to <40% of non-HIV–specific VHH (Derdeyn 
et al., 2000; Wei et al., 2002; Li et al., 2005) and stratified as 
strong if the RLUs were reduced to <20% and intermediate 
if reduced to <40%. As both MS208.A1 and 93MW956.1 are 
classified as tier 1 pseudoviruses (Mascola et al., 2005), and 
thus relatively easy to neutralize, the VHH identified as 
neutralizing to both a strong and intermediate level in the 
initial screen were reexpressed and assessed for their ability to 
neutralize four tier 2/3 viruses: subtype C ZM214M.PL15, 
subtype B THRO4156.18, subtype A 92UG037, and CRF_AG 
(circulating recombinant form AG) T257-31. Individual 
sequences were obtained for 8 of the 2,816 VHH clones 
screened that were able to neutralize one or more of these 
tier 2 pseudoviruses. The level of antigen specificity in VHH 
that did not neutralize in this screen was not comprehen-
sively investigated, although to date, 48 unique sequences 
into a phagemid vector for display on filamentous bacterio-
phage M13 (De Haard et al., 2005; Joosten et al., 2005) and 
electroporated in Escherichia coli TG1 cells. Rescue with helper 
phage VCS-M13 and polyethylene glycol precipitation was 
performed as described previously (Marks et al., 1991), and 
a phage stock containing 5 × 1011 pfu/ml was generated. The 
library from llama 8 had a diversity of >107 and VHH inserts 
in >90% of the phagemids.
Direct neutralization screening of the phagemid library 8
Previously, VHH from immunized llamas were isolated from 
phagemid libraries via sequential rounds of biopanning on 
immobilized proteins to enrich the libraries for VHH that 
bind specifically to the protein target under investigation. For 
example, the previously described anti–HIV-1 VHH (Forsman 
et al., 2008) were isolated from fractions of a phagemid 
library that had been previously enriched for the ability to 
bind to Gp120IIIB and then compete with soluble CD4 
(sCD4) . However, it is well established that some anti–HIV-1 
mAbs that can bind efficiently to recombinant Env do not 
neutralize functional virus and are thus termed non-nAbs 
(Mascola and Montefiori, 2010). Indeed, one of the means by 
which HIV-1 evades a protective human immune response is 
by eliciting the production of non-nAbs or strain-specific 
nAbs (Willey and Aasa-Chapman, 2008). Therefore, it was 
hypothesized that enriching the phagemid library for VHH 
that bind most efficiently could result in the preferential se-
lection of strongly binding VHH over strongly neutralizing 
VHH and thus that a direct neutralization screen would be 
preferable to isolate broad and potently neutralizing VHH. 
This hypothesis was supported by the successful isolation of 
two broad and potent human mAbs, PG9 and PG16, via a 
high-throughput neutralization screen of human B cells 
Figure 1. Llama 8 immune response 
evaluation. (A and B) Serial dilutions of 
llama sera obtained on days 0 and 122 were 
incubated on ELISA plates preimmobilized 
with Gp140UG37 (A) or Gp140CN54 (B) recom-
binant ENV. Binding was assessed as  
described in Materials and methods.  
All samples were assayed in triplicate.  
(C and D) Sera taken on days 0 and 122 were 
preincubated with the 92UG037 pseudovirus 
(C) or CN54 viral isolate (D), and neutraliza-
tion activity was assessed as described in 
Materials and methods. All samples were 
assayed in duplicate. Error bars represent 
standard deviation from the mean. (E) ID50 
titers (µg/ml) for sera taken on day 122 
against both homologous viruses and the 
indicated heterologous viruses. Experiments 
were repeated in duplicate and on two inde-
pendent occasions, except for the heterolo-
gous virus neutralization assays which were 
performed once in duplicate.
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with IC50 values of 
<1 µg/ml. Further-
more, J3 neutralized 90, 88, and 86% of viruses from the other 
three remaining subtypes C, G, and CRF_01AE, respectively. 
In total, J3 neutralized 96% of 100 strains tested (Fig. 2 and 
Table S2), significantly more than any other anti-HIV mAbs 
elicited after immunization in an animal model. This includes 
previously characterized anti-HIV VHH that are either lim-
ited in terms of breadth (Forsman et al., 2008; Hinz et al., 
2010; Koh et al., 2010) and/or potency (Strokappe et al., 
2012). The breadth of J3 neutralization compares favorably 
to the 78–93% neutralization seen with the recently isolated 
human mAbs that arose during HIV-1 infection (Walker et al., 
2009, 2011; Burton and Weiss, 2010; Wu et al., 2010).
Neutralization data for a substantial subset of the viruses 
tested in this study have previously been reported for other 
human nAbs that target the CD4-binding site (Wu et al., 
2010). Thus, the neutralization profile of J3 for this subset of 
69 viruses was compared with that for VRC01/2, b12, and 
CD4-Ig (Wu et al., 2010), which were previously tested in the 
same laboratory (Table S3). Within this subset, neutralization 
(defined as an IC50 value <50 µg/ml) was observed for 88.4, 
85.5, 47.8, 92.8, and 94.2% of viruses for VRCO1, VRC02, 
b12, CD4-Ig, and J3, respectively. VRCO1/2 and J3 neutral-
ized all viruses from subtypes A, B, D, and BC, whereas b12 
neutralized 33.3, 72.2, 80, and 60%, respectively, for these 
subtypes (Fig. 3). In addition, J3 neutralized all of the AG 
viruses, whereas VRCO1 neutralized 50% and b12 failed to 
neutralize any AG viruses (Fig. 3). Viruses from subtypes C, 
AE, and D were neutralized in a comparable manner by J3 and 
VRC01/2 and in both cases more effectively than by b12 (Fig. 3). 
However, it is important to note that these comparisons are 
based on IC50 values in microgram/
milliliter and not molar values. Inter-
estingly, there are two viruses (AE 
620345.c1 and C Du172.17) out of the 
subset of 69 that both VRC01/2 and 
have been obtained from llama 8 via a combination of neu-
tralization screening and panning selection. Interestingly, 
periplasmic extract containing one VHH, designated J3, 
neutralized five of the six screening viruses. Therefore, J3 
was subcloned into an expression vector to allow improved 
protein production with a C-terminal His tag to enable puri-
fication via affinity chromatography and quantification of 
both Ab yield and neutralization potency.
J3 neutralizes 96% of HIV-1 strains tested
Initially, VHH J3 was titrated from a starting concentration of 
50 µg/ml against the pseudoviruses used in the direct neutral-
ization screen. For the first two strains tested, MS208.A1 and 
93MW956.1, 50% inhibitory concentration (IC50) values 
were calculated as 6.5 µg/ml and <0.023 µg/ml, respectively 
(Table S2). Furthermore, all four pseudoviruses in the second 
screening panel were also neutralized to <50% of total virus 
(Table S2). Thus, J3 neutralized representatives from subtypes A, 
B, C, and CRF_02AG. Further neutralization assays undertaken 
in two laboratories revealed that J3 also neutralizes pseudovi-
ruses, replication-competent molecular clones, and T cell–grown 
isolates from subtypes D, G, and CRF AE, AC, ACD, and BC 
(Table S2). Notably, among both the B (Keele et al., 2008) 
and C viruses tested are pseudoviruses derived from transmitter/
founder isolates, which are all neutralized with IC50 values of 
<1 µg/ml and 2 µg/ml for subtypes B and C, respectively.
When the neutralization data are stratified by subtype, J3 
exhibits 100% neutralization of all viruses from subtypes A, 
B, D, and CRF_02AG, AC, ACD, BC, and CD (Fig. 2 and 
Table S2). The median IC50 values are 2.77, 0.74, 3.09, 0.6, 
0.99, 4.42, 0.32, and 2.34 µg/ml for these subtypes, respec-
tively, and interestingly, all CRF_BC strains were neutralized 
Figure 2. Breadth of J3 HIV-1 neutral-
ization. Percentage of virus strains neutral-
ized by J3 stratified by subtype as described 
in Materials and methods. To aid compre-
hension, the columns have been subdivided 
to show the percentage of strains from each 
subtype that were neutralized with IC50 
values falling into the intervals indicated in 
the key. The neutralization activity of each 
VHH was assayed in duplicate or triplicate, 
and negative controls included mouse leuke-
mia and rabies pseudoviruses. The majority 
of the panel of viruses were assayed once.
Figure 3. Comparison of breadth of neu-
tralization achieved by VRCO1/2, b12, and 
CD4-Ig. Percent neutralization for the 
matched subset of viruses assayed against by 
J3, VRC01/2, b12, and CD4-Ig (using data 
published by Wu et al. [2010]) was stratified 
by clade.
JEM Vol. 209, No. 6 
Article
1095
Thus, the potent neutralization of these strains by J3 indicates 
this VHH is a suitable candidate for inclusion in microbicide 
formulations to be tested in NHP models.
J3 binds to immunogen HIV Env trimers  
and competes for the CD4-binding site
J3 binding specificities were examined in ELISA (see Materials 
and methods) where it bound to both the llama immunogen 
trimer proteins Gp140CN54 and Gp140UG37 (Fig. 4, A and B). 
Sigmoidal concentration–dependent binding was observed in a 
similar fashion to that seen with the previously isolated, but less 
broadly neutralizing VHH, A12 (Forsman et al., 2008; Hinz 
et al., 2010; Koh et al., 2010). However, the binding curves 
are not identical for both VHH as their interactions with Env 
are distinct from one another, indicating that their interactions 
with Env are qualitatively different as reflected in the strikingly 
superior neutralization profile of J3. In addition, J3 binds to 
monomeric Gp120IIIB derived from HIV-1 strain IIIB, dem-
onstrating that it achieves such a wide breadth of neutralization 
by interacting with HIV-1 Env in a monomer- rather than 
trimer-specific fashion (Fig. 4 C). Thus, J3 binds to Env from 
subtypes A, B, and CRF_BC in a comparable way with the 
less broadly neutralizing VHH A12. However, the nature and 
consequences of the two distinct VHH binding to Env are 
clearly diverse as A12 binds to Gp140UG37 but is unable to 
neutralize the 92UG037 HIV-1 pseudovirus. Therefore, the 
difference seen in neutralization breadth could not have been 
easily predicted by binding ability. This in turn confirms the 
rationale behind the direct neutralization screen undertaken, 
that VHH binding to recombinant Env is not functionally 
equivalent to HIV-1 neutralization as has already been estab-
lished for human mAbs (Poignard et al., 2003).
To assess whether J3 binds, as does A12 (Forsman et al., 
2008) to a CD4-binding site–related epitope, the interaction 
of J3 with a mutant Env derived from HIV-1 strain YU2 
(Gp120YU2) was evaluated compared with wild-type protein. 
The mutant Env contains a single residue mutation at position 
368 of an aspartic acid to an arginine that abolishes CD4 
binding (Li et al., 2007). The binding of J3 was evaluated by 
ELISA, which revealed that the D368R mutation in Env pre-
vents J3 binding as compared with interaction seen with the 
wild-type Env (Fig. 4 D). Many CD4-binding site Abs have pre-
viously been characterized from infected patients (Corti et al., 
2010; Wu et al., 2010; Zhou et al., 2010; Diskin et al., 2011; 
Scheid et al., 2011) and their epitopes characterized via structural 
and mutational methods, including the use of the D368R mu-
tant Env in binding experiments. Thus, from this preliminary ep-
itope analysis, it can be concluded that the J3 epitope is similarly 
affected by mutation of residue 368 as are VRCO1 and b12 but 
not HJ16, which can bind to the D368R Env (Corti et al., 2010; 
Wu et al., 2010). However, the observation that distinct viruses 
are resistant to neutralization by J3 from those that are resistant to 
the highly characterized broadly neutralizing VRC01 implies 
there is also variation in the residues precisely targeted by VRC01 
and J3, and structural studies are underway to define the key 
contacts of J3 within the CD4-binding site.
J3 failed to neutralize (Table S3). Another clade C virus, 
CAP45.2.00.G3, was effectively neutralized by VRCO1/2 
but not by J3, and within the subset of 69 viruses, there are 
6 viruses that are resistant to VRCO1/2 but sensitive to J3. 
A total of four viruses in this study were resistant to neutral-
ization by J3, and as described previously (Wu et al., 2010), 
two of these are also resistant to VRCO1/2-mediated neu-
tralization, whereas the other two, X2160_c2 and 620345.c1, 
are susceptible. Unfortunately, viral sequence data for the 
latter have yet to be established, so sequence analysis of the 
other three resistant viruses was undertaken, and it was 
found that no single amino acid mutation is present in all 
three resistant viruses that is not present in susceptible 
viruses. However, in all three cases, there are multiple muta-
tions relative to the sequences of closely related virus se-
quences. Therefore, it is hypothesized that multiple clusters 
of mutations contribute to the J3 resistance as has been de-
scribed for naturally occurring viral resistance to VRCO1/2 
(Li et al., 2011), albeit in a distinct way as indicated by the 
different susceptibilities of distinct viruses to neutralization 
by VRC01/2 or J3.
J3 neutralizes all chimeric simian-HIV (SHIV) strains tested
To further characterize J3 and to evaluate its potential as an 
anti-HIV microbicide, its ability to neutralize SHIV pseudo-
viruses was investigated. J3 was found to potently neutralize 
six SHIV pseudoviruses from subtypes B and C, with IC50 
values all <0.5 µg/ml. The clade C SHIVs were in fact 
potently neutralized with IC50 values of <0.02 µg/ml. The 
strains assayed included one derived from SHIV1157IP EL-p, 
a clade C SHIV strain which has been used in recent 
mucosal challenges in NHPs (Humbert et al., 2008), and 
SHIV1157IPD3N4 (Table 1), a highly replication-compe-
tent, mucosally transmissible clade C R5 SHIV which rapidly 
induces abnormalities in immune parameters and could there-
fore be used to assess post–acute viremia levels as readout pa-
rameters of vaccine or microbicide efficacy (Song et al., 2006). 
Table 1. SHIV neutralization by J3
SHIV pseudovirus Clade IC50 in TZM-bl cells
J3 VHH
µg/ml
SHIVsf162p4 B 0.0685
SHIVsf162p3 B 0.2154
SHIV89.6p B 0.4215
SHIV89.6 B 0.1528
SHIV1157IPD3N4 C 0.01976
SHIV1157IP EL-p C 0.006205
VHH J3 neutralization activity was assessed in the indicated SHIV 
pseudoviruses, as described in Materials and methods. The derivation of 
SHIV1157IPD3N4 and SHIV1157IP EL-p is described in detail in Humbert  
et al. (2008). The SHIV neutralization activity of J3 was assayed in duplicate  
on TZM-bl cells as described in Materials and methods, the subtype B SHIVs 
assays were undertaken once, and the subtype C SHIVs were assayed in two 
independent experiments.
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the Gp41-specific mAb 2F5, did not 
compete with biotinylated J3 binding 
(Fig. 5 C). Thus, J3 competes with both 
sCD4 and a previously characterized 
human mAb, b12 (Burton et al., 1994), 
indicating that J3 targets the CD4- 
binding site effectively to achieve its neutralization breadth across 
a wide range of HIV-1 subtypes by interacting with invariant 
residues that are conserved in Env. The precise nature of these 
interactions will be defined by structural studies.
Affinity maturation of J3 resulted in a shortened CDR2 
(complementarity determining region 2)
Analysis of the amino acid sequence (Fig. 6 A) of J3 revealed 
it is part of a distinct phylogenetic family as compared with 
previously described 
anti–HIV-1 VHH 
(Fig. S1; Forsman 
et al., 2008; Hinz 
et al., 2010; Koh et al., 
2010). The most stri-
king aspect of the 
Competition ELISA experiments further showed that J3 
preincubation with Gp140 competed with sCD4 for binding to 
the HIV-1 Env (Fig. 5 A), as did the previously described VHH 
A12 (Forsman et al., 2008), in contrast to the negative control 
(an anti–HIV-1 VHH which was not specific for the CD4-
binding site). In addition, preincubating J3 with the HIV-1 Env 
competed with the anti-CD4 human mAb b12, as did preincu-
bation with the VHH A12, whereas the control VHH did not 
compete with b12 (Fig. 5 B). Furthermore, preincubation of 
A12 with HIV-1 Env competed with biotinylated J3 for binding 
to Gp140, although unlabeled J3 itself appeared to bind with a 
higher affinity than A12 and thus competed more efficiently 
with biotinylated J3. This implies that J3 and A12 bind partially 
overlapping epitopes within the CD4-binding site but that J3 
probably has a higher affinity for its epitope within the CD4-
binding site than does A12, whereas the control in this case, 
Figure 4. J3 binding to trimeric and  
monomeric Env in ELISA. (A and B) VHH 
binding to subtype A Gp140UG37 (A) and CRF 
BC Gp140CN54 (B) was assessed by ELISA.  
Recombinant Envs were immobilized, tripli-
cate serial dilutions of VHH A12, J3, and a 
negative control VHH were added, and bind-
ing was detected as described in the Materials 
and methods. (C and D) Monomeric subtype B 
Gp120IIIB (C) and D368R or wild-type mono-
meric subtype B Gp120YU2 (D). All error bars 
represent standard deviation from the mean. 
All data are representative of at least two 
independent experiments
Figure 5. J3 competition for the CD4-
binding site of HIV-1 Env in ELISA. (A) Dose-
dependent competition of VHH A12, J3, and  
a negative control VHH with sCD4 for  
binding to Gp140UG37. Recombinant Env was 
immobilized, and duplicate 10-fold serial 
dilutions of the indicated VHH were added, 
followed by 0.1 µg/ml sCD4. sCD4 binding to 
Env was detected as described in Materials 
and methods. (B) Dose-dependent competi-
tion of VHH A12, J3, and a negative control 
VHH with mAb b12 for binding to Gp140UG37. 
Recombinant Env was immobilized, and dupli-
cate 10-fold serial dilutions of the indicated 
VHH were added, followed by 1 µg/ml b12. 
Binding to Env was detected as described in 
Materials and methods. (C) Dose-dependent 
competition of VHH J3 and A12 with biotinyl-
ated J3 for binding to Gp140UG37. Recombi-
nant Env was immobilized, and triplicate 
fivefold serial dilutions of the indicated mAb 
or VHH were added (including a negative 
control mAb 2F5), followed by 0.5 µg/ml of 
biotinylated J3. Biotinylated J3 binding was 
detected as described in Materials and meth-
ods. All error bars represent standard deviation 
from the mean. All data are representative of 
at least two independent experiments.
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present in the postimmune sera, which may have masked the 
J3 neutralization activity (not depicted). Based on the screen-
ing protocol used in this study, the frequency of J3-like clones 
is <0.04% of the VHH repertoire and 0.012% of the total Ab 
repertoire. Therefore, future immunogens aiming to elicit a 
J3-like response will need substantial improvement to in-
crease the amount of specific stimulation.
In addition to the shortened CDR2, there are 25 sepa-
rate sites where residues deviate from their germline sequence 
counterparts, including residues located both in the CDRs 
and in framework regions (Fig. 6 A). These residues have 
been altered during the maturation of the J3 heavy chain–
only Ab and may play important roles in the function of the 
VHH. This hypermutation from the germline confirms that 
J3 was indeed the result of affinity maturation in response to 
an antigen that the llama immune system encountered, in 
this case the two subtype HIV-1 Env immunogens used in 
immunization. Analysis of nAbs isolated from HIV-1–infected 
patients has implied that a substantial degree of affinity 
maturation is necessary to produce effective neutralization 
(Burton et al., 1994; Walker et al., 2009; Scheid et al., 
2011), and the divergence of J3 from its germline se-
quence is characteristic of such affinity maturation. Re-
cently, a convergence of residues found in the heavy chains 
of patient-derived broadly neutralizing anti–HIV-1 mAbs 
has been reported (Scheid et al., 2011). To establish how 
similar llama heavy chain–only Abs are to human heavy 
chains, the nucleotide sequences of both J3 and A12 were 
compared with available human heavy chain sequences 
(Fig. 7). The human VH3-23*04 sequence shares 79.57% 
homology with the V gene segment of J3 and 84.38% ho-
mology with that of A12. Notably, this level of homology 
was not greatly different from the 85.60% homology that J3 
shares with its precursor llama germline V gene sequence 
indicated in Fig. 6. Furthermore, the human JH*02 se-
quence shares 83.33% homology with the J gene segment of 
J3 and 78.72% homology with A12 (Fig. 7).
sequence is a deletion in CDR2, reducing its size from 8 to 5 aa. 
Insertions and substitutions in both CDR2 and CDR3 of 
human anti–CD4-binding site mAbs have been shown to be 
of critical importance for potency by altering the interaction 
with the inner domain and bridging sheet of Env (Diskin et al., 
2011). The deletion in the CDR2 of J3 may be required to 
enable the precise binding of this extremely broad neutraliz-
ing anti–HIV-1 VHH to its epitope, and a mutant J3 in 
which the corresponding three germline residues have been 
reinserted can no longer bind to Env (Fig. 6 B). The role of 
CDR2 in the J3–Env interaction will be further clarified by 
structural studies. Notably, such a deletion can be considered 
rare as a comparison of sequences of 1,014 different VHH 
showed only one CDR2 deletion of 3 aa (not depicted).
This deletion in CDR2 is the result of affinity maturation 
as it is not present in the germline sequence (Fig. 6 A) deter-
mined for J3 (determined using 23 V genes from L. glama and 
7 J genes from Lama pacos [not depicted]). The 23 unique V 
genes encoding VHH (based on analysis of >180 clones) can be 
separated in several families based on the presence of the 
motifs KEREG, KQREL, and KEREF. J3 is derived from 
the family typified by the KEREF motif. Within this family, 
there are two very similar germlines, designated Vt and Vs. 
Both of these germline sequences encode the same amino 
acid sequence. However, aligning the J3 DNA sequence with 
that of both Vs and Vt germlines using both Blast and ClustalX 
programs shows Vt to be the most closely aligned germline 
to J3. However, it should be noted that in the absence of the 
sequencing of the full L. glama genome, it is possible that 
additional V genes exist that are more closely related than Vt 
to J3. A family-specific approach (Koh et al., 2010) will be 
used to isolate further VHH clones related to J3 and enable 
estimation of the frequency of J3-like clones in the library. 
However, there is some disparity between the low level of 
neutralization seen with the postimmune sera compared with 
the breadth and potency of J3. Given the previous isolation 
of multiple VHH from the same V gene germline, it is un-
likely this disparity is caused by a rare germline precursor but 
rather suboptimal stimulation and proliferation of the J3- 
secreting B cell clone. In addition, no J3-inhibitory activity was 
Figure 6. J3 amino acid and germline sequences. (A) J3 
amino acid sequence as determined by purified pCAD51 A12 
DNA and J3 germline determined based on sequence data 
(unpublished data) and DNA analysis of the area on which 
the V and J genes encoding VHH are located on the L. glama 
and L. pacos genomes. Residues that deviate from germline 
outside the CDRs are highlighted in yellow, and those inside 
CDR1 and CDR2 are highlighted in red. Note that the portion 
of the VHH sequence arising from the D genes (mapping to 
CDR3) is too small to enable alignment via ClustalW or 
BLAST with D genes from L. glama or L. pacos, and no signifi-
cant association is found, thus the gap in the germline de-
picted. (B) VHH binding to subtype A Gp140UG37 was assessed 
by ELISA. Recombinant Envs were immobilized, triplicate 
serial dilutions of mutant, wild-type J3, or a negative control 
VHH were added, and binding was detected as described in 
Materials and methods. All error bars represent standard 
deviation from the mean. All data are representative of at 
least two independent experiments.
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Env and/or compete with nAbs. However, to 
isolate a VHH specific for a particular binding 
site on Env, the original biopanning method 
remains advantageous, as it enables targeted 
selection of VHH via enriching for those VHH 
that compete with a known nAb to a specific 
region. As Env glycoproteins were used to elicit 
J3 and given that patient-derived nAbs have 
been shown to provide protection from infec-
tion when passively infused into NHPs (Mascola 
et al., 1999, 2000; Burton et al., 2011; Watkins 
et al., 2011), these recombinant immunogens 
represent valid vaccine candidates for HIV. However, given 
the weak level of serum neutralization observed, they will re-
quire further modification to induce high titer J3-like broad 
cross-neutralizing serum responses.
J3 neutralizes 96% of all strains tested in this study, which 
included 100 representatives from a wide range of subtypes 
and CRFs. In fact, J3 neutralizes 100% of subtype A, B, D, and 
CRF AC, ACD, AG, BC, and CD and >85% of the remaining 
subtypes tested, C, G, and CRF AE. In an analysis of viruses 
previously tested against VRCO1/2 and b12, J3 neutralized 
94.2% of viruses (this study) compared with VRCO1, which 
neutralized 88.4% of the subset of 69 viruses (Wu et al., 2010). 
Sensitivity to the full-length human nAb and the llama VHH 
were similarly distributed across different subtypes in this 
subset. However, at the level of individual viruses, resistance 
to VRCO1 did not confer resistance to J3 and vice versa. No 
clear pattern of residues associated with J3 resistance was dis-
cernible from analysis of the available sequences for viruses 
that were not neutralized by J3. Although the evaluation of J3 
against additional viruses may provide further insight into 
key residues for J3-mediated neutralization, it may be more 
thorough to evaluate the neutralization sensitivity of a panel 
of engineered viral mutants to define the functional J3 epitope 
in combination with escape mutant studies.
J3 binds to both the trimeric immunogens that llama 8 
received as well as monomeric Gp120IIIB and Gp120YU2. J3 
targets the binding site of Env for the HIV-1 cellular receptor 
CD4 as confirmed by the loss of binding seen with the CD4-
binding site D368R Gp120YU2 mutant relative to wild-type 
Gp120YU2. In addition, J3 competes with sCD4 itself as well 
as with the well-characterized human mAb b12. Competition 
experiments with A12, a previously isolated anti–CD4-binding 
site VHH, showed that binding assays, while demonstrating a 
DISCUSSION
The isolation of J3 represents a significant improvement on 
previous nAbs derived from immunized animals as in single-
domain VHH form it has a comparable breadth and potency 
to the best nAbs obtained from a limited number of natural 
human infections. In contrast, previous nAb clones charac-
terized from immunized animals have only exhibited limited 
breadth (Forsman et al., 2008; Sundling et al., 2010). A 
caveat to this is the observation that sera with 17b-like bind-
ing specificity can be induced after immunization of humans 
(Vaine et al., 2010), and it should be noted that 17b and other 
Abs to CD4-induced epitopes are less broadly neutralizing as 
full-length mAbs than in Fab form (Labrijn et al., 2003). 
However, given the previously reported decrease in neutral-
ization ability seen with the Fab of b12 (Labrijn et al., 2003), 
it appears the CD4-binding site of Env is not per se more 
easily targeted for neutralization by small Ab fragments as is 
the CD4-induced binding site, presumably because of the 
required presence of the coreceptor interacting with Env in 
the latter case. As J3 neutralizes via interaction with the CD4-
binding site, it is unlikely that its breadth is a function solely 
of the smaller size of VHH. Therefore, whether the breadth 
and potency of J3 are conserved in a full-length heavy chain–
only llama Ab will be investigated. Thus, this study reports 
for the first time an nAb response after experimental immu-
nization with a breadth equivalent to that seen in the best Ab 
responses in natural infection.
Llama 8 was multiply immunized with trimeric Gp140 
Env derived from a subtype A and CRF BC viruses in the 
presence of the adjuvant Stimune. The resulting phagemid 
VHH library was screened via a selection method based on 
neutralization function rather than pre-enriching a polyclonal 
mixture of VHH for the ability to bind to recombinant HIV-1 
Figure 7. Phylogenetic relationship of heavy chain 
V genes from llamas and humans. (A) J3 and A12 
sequences were aligned with human germline IgVH 
sequences through the VQUEST tool of IMGT (http://
www.IMGT.org; GenBank/EMBL/DDBJ accession  
no. AJ879486). (B) J3 sequence was aligned with human 
germline IgVH sequences through the VQUEST tool of 
IMGT (GenBank accession no. AJ879486). Residues that 
differ in the VHH sequence as compared with the human 
germline are underlined.
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the CD4-binding site demonstrated by J3 has only previ-
ously been seen as a result of natural infection (Corti et al., 
2010; Wu et al., 2010; Scheid et al., 2011). The definition 
of the precise CD4-binding site epitope targeted by J3 will 
be clarified by structural studies and may be used to opti-
mize future immunogens, which can be easily and effi-
ciently evaluated using this redefined screening process for 
llama VHH libraries.
MATERIALS AND METHODS
mAbs. mAb b12 (Burton et al., 1991) and 2F5 (Buchacher et al., 1994) 
were obtained through the Centralized Facility for AIDS Reagents (CFAR), 
National Institute for Biological Standards and Controls (NIBSC), supported 
by the EC FP6/7 EUROPRISE Network of Excellence, Next Generation 
HIV-1 Immunogens inducing broadly reactive Neutralising antibodies 
(NGIN) Consortium, and the Bill and Melinda Gates Global HIV Vaccine 
Research Cryorepository–Collaboration for Aids Vaccine Discovery 
(GHRC-CAVD) Project, and were donated by D. Burton (The Scripps 
Research Institute, La Jolla, CA) and H. Katinger (Polymun Scientific, 
Vienna, Austria), respectively.
Recombinant HIV-1 Env proteins. Recombinant trimeric Gp140 from 
HIV-1 92UG037 (subtype A) for immunizations and ELISAs was provided 
by S. Jeffs (Imperial College London, London, England, UK). Recombi-
nant trimeric Gp140 derived from HIV-1 CN54 for immunizations was 
provided by Polymun Scientific. Recombinant D368R and wild-type 
monomeric Gp120 from HIV-1 YU2 (subtype B) for ELISAs were pro-
vided by J. Mascola (National Institutes of Health [NIH], Bethesda, MD). 
Recombinant Gp120 from HIV-1 IIIB (EVA657) and recombinant 
trimeric Gp140 from HIV-1 CN54 (ARP699) for ELISAs were obtained 
from the CFAR, NIBSC and were donated by Immunodiagnostics and 
Polymun Scientific, respectively.
Viruses. HIV-1 IIIB (ARP101) and YU2 were obtained from the CFAR, 
NIBSC. IIIB was donated by R. Gallo and M. Popovic (University of Mary-
land School of Medicine, Baltimore, MD). HIV-1 CRF07_BC primary iso-
late CN54 was obtained from EMPRO. HIV-1 IIIB was propagated in H9 
cells, and CN54 was propagated in peripheral blood mononuclear cells. All 
other replication-competent virus stocks were prepared from HIV-1 molec-
ular clones by transfection of 293T cells. The 92BR025.C1 (C111) molecular 
clone was obtained by amplifying Gp120 from cells infected with the WHO 
panel peripheral blood mononuclear cell–grown isolate and inserting it into 
the pHXB2 backbone (Forsman et al., 2008). HIV-1 Env pseudotyped 
viruses were produced in 293T cells by cotransfection with the pSG3env 
plasmid (Kirchherr et al., 2007). The subtype B and C HIV-1 Reference 
Panels of Env Clones (Li et al., 2005, 2006) were obtained through the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, 
National Institute of Allergy and Infectious Diseases (NIAID), NIH. HIV-1 
subtype CRF07_BC Gp160 clones, subtype CRF02_AG Gp160 clones 
(263-8, T278-50, and T266-60), and the 92UG037, 93MW965.26, and 
96ZM651.02 Gp160 clones were provided by D. Montefiori (Duke Uni-
versity Medical Center, Durham, NC) through the Comprehensive Anti-
body Vaccine Immune Monitoring Consortium (CA2 VIMC) as part of 
the CAVD. All additional pseudoviruses were produced at the CAVD Pre-
clinical Neutralizing Antibody Core laboratory. Virus CVS-11 pseudotyped 
with rabies virus G protein (Wright et al., 2008) was provided by E. Wright 
(University of Westminster, London, England, UK).
Cells. TZM-bl cells (Derdeyn et al., 2000; Wei et al., 2002; Li et al., 2005) 
were obtained through the NIH AIDS Research and Reference Reagent Pro-
gram from J.C. Kappes (University of Alabama at Birmingham, Birmingham, 
AL), X. Wu (NIAID, NIH), and Tranzyme, Inc. and cultured in Dulbecco’s 
modified Eagle medium (Invitrogen) containing 10% (vol/vol) FCS.
level of difference between the two VHH, were not able to 
detect the disparity between these two VHH in terms of neu-
tralization ability. Together with the level of neutralization 
breadth observed, these findings indicate that J3 recognizes part 
of the Env CD4-binding site and very few if any of the adjacent 
amino acids, although this remains to be defined in detail.
This study describes the isolation of an extremely broad 
and potent HIV-1–neutralizing VHH, J3, from a screen of 
almost 3,000 clones. This method provides a relatively quick 
screening process compared, for example, with the 30,000 
human B cell clones screened to isolate the PG9 and PG16 
nAbs (Walker et al., 2009). Thus, this method could be used 
alongside testing the immune sera for neutralization to evaluate 
new HIV-1 immunogens in the established llama model, 
accelerated by the advantage of heavy chain–only Abs that 
they do not require heavy and light chain random recombi-
nation. Furthermore, the independently functional nature of 
the VHH Ab fragments (Vanlandschoot et al., 2011) coupled 
with their intrinsic stability (Gorlani et al., 2012) makes them 
suitable candidates for anti–HIV-1 microbicide development. 
Thus, broad and potent neutralizing VHH isolated in this 
way, such as J3, can both aid progress toward an HIV-1 
vaccine and simultaneously provide a useful reagent for anti-
HIV therapeutics and/or prophylaxis.
Recently, the precedent for an anti–HIV-1 microbicide 
has been established by the successful phase III trial of an 
antiretroviral-containing gel (Abdool Karim et al., 2010). 
Furthermore, immunological microbicides, such as mAbgel 
(Brinckmann et al., 2011), are under investigation. A VHH 
with the breadth of J3 has potential as the active component 
of such a microbicide because of the intrinsic temperature 
and pH stability of VHH (Gorlani et al., 2012) and the ease 
and low cost with which they can be manufactured as com-
pared with full-length human nAbs. In addition, J3 neutral-
izes a range of SHIV strains as well, making it an ideal 
candidate for SHIV mucosal challenge experiments either via 
passive immunization or in a microbicide formulation. The 
potential use of microbicides is not mutually exclusive with 
that of a vaccine, as the two could be complementary in a 
situation whereby an effective microbicide could limit the 
probability infection and thus support a vaccine-induced 
immune response.
In conclusion, the isolation of such a potent and broad 
VHH fragment from an animal immunized with a relatively 
simple combination of recombinant protein immunogens 
argues for the potential of vaccination to elicit cross-reactive 
protective anti-HIV Abs, and further study of this VHH will 
provide insight into how to recapitulate the elicitation of 
such Abs, hopefully in conventional IgG format. VHH J3 
neutralizes 96% of all strains tested to date, and these include 
a great variety of HIV-1 subtypes. This highly cross-reactive 
anti–HIV-1 VHH differs from previous anti–HIV-1 VHH 
not only in its breadth but in terms of the immunization pro-
cedure undertaken, the screening method by which it was 
isolated and its phylogenetically distinct and affinity-matured 
sequence. The breadth of neutralization achieved via targeting 
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and a molecular clone of SHIV1157ipd3N4 were provided by R. Ruprecht 
(Dana-Farber Cancer Institute), and SHIVSF162p3 was a gift of C. Cheng-
Mayer (Aaron Diamond AIDS Research Center, New York, NY). 
SHIVSF162P4 was obtained from the Division of AIDS, NIAID, NIH.
Pseudotyped SHIV viruses were prepared by E.J. Verschoor and 
Z. Fagrouch (Biomedical Primate Research Centre [BPRC], Rijswijk, 
Netherlands) essentially as described by Wei et al. (2002). In short, the full-
length env genes were amplified from molecularly cloned viruses or from viral 
RNA, and the PCR products were cloned into the expression plasmid 
pcDNA3.1 (Life Technologies). Individual clones were sequenced and se-
lected for their suitability to produce pseudoviruses in a small-scale infection 
assay on TZM-bl indicator cells before performing neutralization assays 
(Montefiori, 2005). For this purpose, small stocks of pseudotyped viruses were 
prepared by transfection of 293T cells with a mixture of the pcDNA-env 
plasmid and the pSG3env plasmid, which contains an Env-deficient molec-
ular clone of HIV-1 SG3 (Kirchherr et al., 2007). After incubation, cell-free 
virus stocks were produced by low-speed centrifugation, followed by filtration 
through a 45-µm filter, and used to infect TZM-bl cells. Viruses that induced 
luciferase activity were selected for the pseudovirus neutralization assay.
The neutralization activity of the VHH was assayed in duplicate at the 
BPRC laboratory in the TZM-bl cell-based assay developed by Derdeyn 
et al. (2000), Wei et al. (2002), and Li et al. (2005), containing 15 µg/ml 
DEAE-Dextran, and assayed with Britelite Plus Reagent (PerkinElmer) 
according to manufacturer’s instructions using a Victor light plate reader 
(PerkinElmer). VHH IC50 titers were calculated using the Luc5Samples02-
NotProtected.xls program (courtesy of D. Montefiori).
ELISAs. Clear 96-well MaxiSorp plates (Thermo Fisher Scientific) were 
coated overnight with 2 µg/ml HIV-1 Gp120IIIB or Gp140UG37. Plates were 
blocked using 5% milk powder in TBS. Serial dilutions in TBS supple-
mented with 0.05% Tween (TBS-T) containing 1% milk powder (TMT) 
of the VHH to be assayed and of a negative control VHH were then added 
to the plates in triplicate wells, and the plates were incubated at room 
temperature for 1 h and subsequently washed four times with TBS-T. The 
wells were then incubated with 0.5 µg/ml mouse anti–c-Myc–horseradish 
peroxidase–conjugated Ab (Roche) in TMT for 1 h at room temperature. 
After six washes with TBS-T, TMB ELISA substrate (Thermo Fisher 
Scientific) was added, and the plates were incubated at 37°C for 0.5 h. Absor-
bance at 450 nm was detected, and background-subtracted data were plotted 
against VHH concentration.
Immune response ELISAs. 50 µl of 2 µg/ml Gp140CN54 and Gp140UG37 
was coated on MaxiSorp plates overnight at 4°C. After blocking with 4% 
milk powder in PBS, serial dilutions of preimmune serum (day 0) and 
immune plasma (day 122) were incubated for 1 h in triplicate. The serum 
and plasma were diluted in 1% milk powder in PBS by serial dilution from 
500- to 32,000-fold, with twofold dilution steps in between. Detection of 
bound llama single chain Abs was performed by incubation with mAb 8E1 
followed by an incubation with peroxidase-conjugated donkey anti–mouse 
Ig (1:5,000 in 1% milk powder in PBS). Anti–llama IgG3 mAb 8E1 was 
provided by BAC BV. 50 µl O-phenylenediamine containing 0.03% H2O2 
was added to the wells. After 5 min, the reaction was stopped with 1 M 
H2SO4. The absorbance of the reaction was measured at 490 nm.
Competition ELISAs. Clear 96-well MaxiSorp plates were coated over-
night with 2 µg/ml Gp140UG37 and washed three times with PBS with 0.05% 
Tween (PBS-T). Plates were blocked using 4% milk powder in PBS and 
then washed three times in PBS-T. Serial dilutions in PBS-T supplemented 
with 1% milk powder (PBS-M) of the VHH to be assayed and of a negative 
control VHH were then added to the plates in duplicate/triplicate wells as 
indicated in the figure legends, and the plates were incubated at room 
temperature for 1 h. The wells were then incubated with either 1 µg/ml b12 
or 0.1 µg/ml sCD4 in PBS-M for 1 h at room temperature. After three 
washes with PBS-T, the wells were incubated with either 1:5,000 goat anti–
human peroxidase or 1:10,000 L120 in PBS-M for the b12 and sCD4 wells, 
Immunization of L. glama and construction of the VHH phage 
library. Llama 8 was immunized with recombinant Gp140 derived from 
HIV-1 CN54 and 92UG037. Immunizations and VHH library construction 
were performed as described previously (De Haard et al., 2005). In brief, the 
llamas received seven intramuscular injections as per Table S1. Each injec-
tion consisted of a freshly prepared 4.5-ml water in oil emulsion prepared by 
vigorously mixing 2 vol U of antigen (50 or 100 µg) with 2.5 vol U of the 
adjuvant Stimune (CEDI Diagnostics). This study was performed in strict 
accordance with the Dutch Experiments on Animals Act 1997. In accor-
dance with article 18 of the Act, the protocol was assessed and approved 
by the Animal Ethics Committee of Utrecht University (permit number: 
DEC#2007.III.01.013). All efforts were made to minimize discomfort re-
lated to immunizations and blood sampling. The animal welfare officers of 
Utrecht University checked the mandatory administration and supervised 
the proper conduct of procedures and the well-being of the llamas that were 
used. The anti-Env immune response in sera was verified in an ELISA 
against immobilized recombinant Gp120IIIB. Total RNA was isolated from 
peripheral blood lymphocytes collected after immunization (on day 122), 
and cDNA was prepared. The VHH repertoire was amplified and cloned 
into the pCAD50 phagemid vector. To obtain recombinant bacteriophages 
expressing the VHH as fusion proteins with the M13 bacteriophage gene III 
product, transformed TG1 E. coli cells were grown to logarithmic phase and 
then infected with helper phage M13KO7. The phage particles were pre-
cipitated with polyethylene glycol.
Isolation of anti–HIV-1 VHH through direct HIV-1 neutralization 
screening. Phages expressing the cloned VHH repertoire were plated onto 
agar containing 100 µg/ml ampicillin and 2% syncytial stain (1 g methylene 
blue and 0.33 g basic fuchsin in 200 ml methanol). Individual clones were 
picked using a Norgren CP7200 colony picker (RapidPick; Hudson 
Robotics) into 384-well master plates. 2,816 individual clones were expressed 
in TG1 E. coli cells in a 96-well plate format. Each clone was expressed in 1 ml 
of 2× TY medium containing 100 µg/ml ampicillin and 0.1% glucose, 
followed by induction of VHH production with 0.1 mM isopropyl--d-
thiogalactopyranoside. Bacterial pellets were frozen at 80°C for a minimum 
of 1 h and then thawed and resuspended in PBS. The periplasmic extract from 
each well was separated from bacterial debris by filtration through a 0.2-µM 
polyvinylidene fluoride membrane and screened for the ability to neutralize 
HIV-1. To enable semi–high-throughput screening and characterization of 
VHH, neutralization was measured using 200 50% tissue culture infective doses 
of virus in the TZM-bl cell-based assay developed by Derdeyn et al. (2000), 
Wei et al. (2002), and Li et al. (2005), with Bright-Glo luciferase reagent (Pro-
mega) using a Glomax plate reader (Promega). DNA from the individual VHH 
that neutralized all viruses to <20% seen with control was purified, sequenced, 
and recloned into the pCAD51 expression vector followed by transformation 
into TG1 cells for purification and further characterization. The HIV-1 neu-
tralization potencies of llama 8 sera were also evaluated in TZM-bl cells as de-
scribed above. Serum samples were heat-inactivated to destroy complement 
by incubation at 56°C for 1 h before use in neutralization assays. Threefold se-
rial dilutions of llama sera were then tested, starting at a 1:5 dilution.
VHH purification and neutralization profiling. Expression from the 
pCAD51 vector incorporates a 6-His and a c-Myc tag to the C terminus of 
the VHH and removes the bacteriophage gene III product. The VHH were 
purified by means of the attached His tag using TALON Metal Affinity 
Resin (Takara Bio Inc.). The neutralization activity of the VHH was assayed 
in duplicate/triplicate at either University College London or VIMC labo-
ratories. No virus inactivation was observed with a negative control VHH or 
with a pseudovirus bearing a rabies virus G-protein Env or mouse leukemia 
virus Env. VHH IC50 titers were calculated using the XLFit4 software 
(UCL-ID Business Solutions) or the Labkey Neutralizing Antibody Tool 
(Piehler et al., 2011).
SHIV. Molecularly cloned SHIV 89.6p and HIV-1 89.6 were obtained 
from J. Sodroski (Dana-Farber Cancer Institute, Boston, MA) through the 
NIH AIDS Research and Reference Reagent Program. SHIV1157ipEL-p 
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included as an Excel file, reiterates the IC50 titers (µg/ml) for VRC01/2, 
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69 matched viruses against which J3 was also tested. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20112655/DC1.
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